Pfizer Inc. (NYSE:PFE) Shares Sold by Peak Financial Advisors LLC

Peak Financial Advisors LLC lowered its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 72.9% in the second quarter, Holdings Channel reports. The institutional investor owned 3,996 shares of the biopharmaceutical company’s stock after selling 10,736 shares during the quarter. Peak Financial Advisors LLC’s holdings in Pfizer were worth $210,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Ullmann Wealth Partners Group LLC increased its holdings in Pfizer by 6.2% in the 1st quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company’s stock valued at $298,000 after purchasing an additional 335 shares during the last quarter. Red Door Wealth Management LLC increased its holdings in Pfizer by 8.6% in the 1st quarter. Red Door Wealth Management LLC now owns 109,620 shares of the biopharmaceutical company’s stock valued at $5,675,000 after purchasing an additional 8,694 shares during the last quarter. Capital City Trust Co. FL increased its holdings in Pfizer by 49.9% in the 1st quarter. Capital City Trust Co. FL now owns 8,464 shares of the biopharmaceutical company’s stock valued at $438,000 after purchasing an additional 2,816 shares during the last quarter. Colonial River Wealth Management LLC increased its holdings in Pfizer by 52.3% in the 1st quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 7,206 shares during the last quarter. Finally, Annex Advisory Services LLC increased its holdings in Pfizer by 23.6% in the 1st quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company’s stock valued at $532,000 after purchasing an additional 1,966 shares during the last quarter. Institutional investors and hedge funds own 67.90% of the company’s stock.

Pfizer Trading Up 1.5 %

NYSE PFE opened at $44.57 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. The firm has a market cap of $250.14 billion, a PE ratio of 8.72, a P/E/G ratio of 0.54 and a beta of 0.70. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71. The firm’s fifty day moving average is $48.40 and its two-hundred day moving average is $50.33.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. The company had revenue of $27.74 billion for the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. Pfizer’s quarterly revenue was up 46.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 earnings per share. Analysts expect that Pfizer Inc. will post 6.54 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Stockholders of record on Friday, November 4th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio (DPR) is 31.31%.

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a research report on Tuesday, June 28th. Morgan Stanley decreased their price target on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a research report on Friday, July 8th. Berenberg Bank set a $44.00 price target on shares of Pfizer in a research report on Wednesday, September 14th. Barclays set a $50.00 price target on shares of Pfizer in a research report on Thursday, September 1st. Finally, SVB Leerink decreased their price objective on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research report on Friday, July 29th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $57.00.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.